MARKET

NYMX

NYMX

Nymox
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.450
+0.180
+5.50%
Closed 16:01 07/15 EDT
OPEN
3.330
PREV CLOSE
3.270
HIGH
3.570
LOW
3.290
VOLUME
122.98K
TURNOVER
--
52 WEEK HIGH
4.790
52 WEEK LOW
1.580
MARKET CAP
247.01M
P/E (TTM)
-18.6185
1D
5D
1M
3M
1Y
5Y

NYMX News

More
Nymox (+8%) on track to file fexapotide applications in ~four months
Seeking Alpha - Article · 06/19 15:54
Nymox Announces Updates in Regulatory Submissions For Fexapotide Treatment For Prostate Enlargement
GlobeNewswire · 06/19 14:30
Nymox Pharma Offers Update On Regulatory Submissions For Fexapotide Treatment For Prostate Enlargement
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is very pleased to report that key steps in its regulatory submission preparations have been completed and the project is firmly on-track. The majority of its regulatory
Benzinga · 06/19 13:31
The Daily Biotech Pulse: GlaxoSmithKline, IDEAYA Strike Oncology Partnership, Decision Day For Merck, Adverum's New CEO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 16)
Benzinga · 06/16 12:15
Hedge Funds Cautiously Watching Pharmaceutical Corporation (NYMX)
Insider Monkey · 06/05 20:16
If You Had Bought Nymox Pharmaceutical (NASDAQ:NYMX) Shares Five Years Ago You'd Have Made 91%
Simply Wall St. · 05/05 14:08
Nymox Announces Important New Patent Developments
GlobeNewswire · 04/21 13:45
Nymox Pharmaceutical Corp Files For Mixed Shelf Offering Of Up To $12M
-Reuters
Reuters · 04/03 17:54

Industry

Biotechnology & Medical Research
+1.30%
Pharmaceuticals & Medical Research
+1.59%

Hot Stocks

Symbol
Price
%Change

About NYMX

Nymox Pharmaceutical Corp is a Canada-based biopharmaceutical company. The Company is focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia (BPH) and the treatment of low-grade localized prostate cancer. The Company operates through the research and development of products for the aging population segment. The Company markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. The Company also owns rights for its marketed products, its investigational drug, as well as other therapeutic and diagnostic indications. The Company also has the rights for the use of statin drugs for the treatment and prevention of Alzheimer's disease. The Company's subsidiaries include Nymox Corporation and Serex, Inc. Nymox Corporation conducts research and development, while Serex, Inc. conducts research and development, and manufacturing of NicAlert and TobacAlert.
More

Webull offers kinds of Nymox Pharmaceutical Corp stock information, including NASDAQ:NYMX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NYMX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NYMX stock methods without spending real money on the virtual paper trading platform.